The present invention relates to the formulation of adenoviral vectors in sorbitol containing compositions in combination with a further amorphous sugar, its formulation as well as a method for obtaining a dried composition.

The present invention relates to the formulation of adenoviral vectors in sorbitol containing compositions in combination with a further amorphous sugar, its formulation as well as a method for obtaining a dried composition.

The disclosure provides recombinant adenoviruses comprising a polynucleotide comprising: a first DNA sequence encoding a guide RNA (gRNA), wherein the gRNA comprises a DNA-binding domain and a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease protein-binding domain, and the DNA-binding domain is complementary to a target sequence in a gene; and a first promoter that is operably linked to the DNA sequence. The disclosure also provides pharmaceutical compositions comprising the adenoviruses described herein. The disclosure further provides a method of treating cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical compositions as described herein to the subject.

Replicating recombinant adenovirus vectors derived from human adenovirus serotype 26 or human adenovirus serotype 35 are described. The replicating recombinant adenovirus vectors have attenuated replicative capacity as compared to that of the corresponding wild-type adenovirus. They can be used for stable expression of heterologous genes in vivo. Also described are compositions and methods of using these recombinant adenovirus vectors to induce an immune response in a subject, and vaccinate a subject against an immunogenic human immunodeficiency virus (HIV) infection.